ADC Therapeutics SA Key Management Personnel Compensation Shortterm Employee Benefits
ADC Therapeutics SA (ADCT) reported Key Management Personnel Compensation Shortterm Employee Benefits of $2.38 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits · last filed 2023-11-07
- ADC Therapeutics SA key management personnel compensation shortterm employee benefits for the quarter ending 2023-09-30 was $2.38M, a 9.37% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation shortterm employee benefits for the quarter ending 2023-06-30 was $2.59M, a 25.46% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation shortterm employee benefits for the quarter ending 2023-03-31 was $3.63M, a 69.36% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation shortterm employee benefits for the quarter ending 2022-12-31 was $4.20M, a 62.00% increase year-over-year.
| Period end | Key Management Personnel Compensation Shortterm Employee Benefits 3 month | Key Management Personnel Compensation Shortterm Employee Benefits 6 month | Key Management Personnel Compensation Shortterm Employee Benefits 9 month | Key Management Personnel Compensation Shortterm Employee Benefits 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.38M 6-K · filed 2023-11-07 | $4.97M derived: sum of 2 quarters · filed 2023-11-07 | $8.60M 6-K · filed 2023-11-07 | $12.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $2.59M 6-K · filed 2023-08-08 | $6.22M 6-K · filed 2023-08-08 | $10.42M derived: sum of 3 quarters · filed 2023-08-08 | $12.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $3.63M 6-K · filed 2023-05-09 | $7.83M derived: sum of 2 quarters · filed 2023-05-09 | $10.01M derived: sum of 3 quarters · filed 2023-11-07 | $12.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $4.20M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $6.38M derived: sum of 2 quarters · filed 2023-11-07 | $8.44M derived: sum of 3 quarters · filed 2023-11-07 | $10.58M 20-F · filed 2023-03-15 |
| 2022-09-30 | $2.18M 6-K · filed 2023-11-07 | $4.24M derived: sum of 2 quarters · filed 2023-11-07 | $6.38M 6-K · filed 2023-11-07 | $8.97M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.06M 6-K · filed 2023-08-08 | $4.21M 6-K · filed 2023-08-08 | $6.80M derived: sum of 3 quarters · filed 2023-08-08 | $9.08M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.14M 6-K · filed 2023-05-09 | $4.74M derived: sum of 2 quarters · filed 2023-05-09 | $7.01M derived: sum of 3 quarters · filed 2023-05-09 | $8.98M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.59M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $4.87M derived: sum of 2 quarters · filed 2023-03-15 | $6.84M derived: sum of 3 quarters · filed 2023-03-15 | $8.87M 20-F · filed 2023-03-15 |
| 2021-09-30 | $2.28M 6-K · filed 2022-11-08 | $4.25M derived: sum of 2 quarters · filed 2022-11-08 | $6.28M 6-K · filed 2022-11-08 | $8.78M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $1.97M 6-K · filed 2022-08-09 | $4.00M 6-K · filed 2022-08-09 | $6.50M derived: sum of 3 quarters · filed 2023-03-15 | $8.44M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $2.03M 6-K · filed 2022-05-09 | $4.53M derived: sum of 2 quarters · filed 2023-03-15 | $6.47M derived: sum of 3 quarters · filed 2023-03-15 | $8.13M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $2.50M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $4.44M derived: sum of 2 quarters · filed 2023-03-15 | $6.10M derived: sum of 3 quarters · filed 2023-03-15 | $7.69M 20-F · filed 2023-03-15 |
| 2020-09-30 | $1.94M 6-K · filed 2021-11-02 | $3.60M derived: sum of 2 quarters · filed 2021-11-02 | $5.19M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $1.67M 6-K · filed 2021-08-03 | $3.25M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $1.60M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $5.36M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $4.51M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |